Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma.

N Engl J Med

From the Department of Medicine, Section of Hematology (S.N., A.R.B., C.S.B., M.V.D.), Section of Digestive Diseases (J.L., P.K.M.), Yale Liver Center (P.K.M.), and Yale Cancer Center (M.V.D.), Yale University School of Medicine, New Haven, CT.

Published: February 2016

Antigen-driven selection has been implicated in the pathogenesis of monoclonal gammopathies. Patients with Gaucher's disease have an increased risk of monoclonal gammopathies. Here we show that the clonal immunoglobulin in patients with Gaucher's disease and in mouse models of Gaucher's disease-associated gammopathy is reactive against lyso-glucosylceramide (LGL1), which is markedly elevated in these patients and mice. Clonal immunoglobulin in 33% of sporadic human monoclonal gammopathies is also specific for the lysolipids LGL1 and lysophosphatidylcholine (LPC). Substrate reduction ameliorates Gaucher's disease-associated gammopathy in mice. Thus, long-term immune activation by lysolipids may underlie both Gaucher's disease-associated gammopathies and some sporadic monoclonal gammopathies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804194PMC
http://dx.doi.org/10.1056/NEJMoa1508808DOI Listing

Publication Analysis

Top Keywords

monoclonal gammopathies
16
clonal immunoglobulin
12
gaucher's disease-associated
12
patients gaucher's
8
gaucher's disease
8
disease-associated gammopathy
8
gammopathies
5
gaucher's
5
immunoglobulin lysolipids
4
lysolipids origin
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!